Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$33.95M$33.95M+21.2% vs Q3 2015 Net Income-$37.11M-$37.11MN/M vs Q3 2015 EPS Diluted-$1.00-$1.00N/M vs Q3 2015 Operating Income-$20,372,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$4,592,000+526.5% Margins · derivedOperating margin-60.0%+13.2 pt vs Q3 2015
Net margin-109.3%
ended Sep 30, 2016 · filed Nov 4, 2016 · 35 d after period end